Skip to Content
Morningstar

Getinge AB Class B GETI B

Morningstar Rating
Unlock
Stock XSTO Rating as of
SEK 232.30 +0.40 (0.17%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Getinge Earnings: Full-Year Guidance Reaffirmed on In-Line Results; Shares Fairly Valued

Jay Lee

Narrow-moat Getinge reported first-quarter results that were in line with our expectations and management reiterated its full-year guidance of 2%-5% organic sales growth. The company also plans to hold an informal update on May 15, which should offer some updated views on the growth trajectories of its end markets and additional color about its cost structure. We maintain our fair value estimate of SEK 236 per share and view shares as fairly valued.

Read Full Report

Price vs Fair Value

View History
GETI B is trading at a 2% discount.
Price
SEK 231.90
Fair Value
SEK 888.00
Uncertainty
High
1-Star Price
SEK 147.80
5-Star Price
SEK 848.80
Economic Moat
Cqgbm
Capital Allocation
Wzjhsshc

Bulls Say, Bears Say

Bulls

Despite ongoing costs related to quality improvement in cardiopulmonary and cardio assist products, once these are resolved the company has a pathway to improving profitability driven by favorable product mix shift and new product launches.

Bears

Regulatory issues have weighed on the company for over 10 years since its FDA consent decree in 2015.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GETI B is a good fit for your portfolio.
Get 7 Days Free

Trading Information

Previous Close Price
SEK 231.90
Day Range
SEK 230.90–234.00
52-Week Range
SEK 174.20–268.80
Bid/Ask
SEK 231.80 / SEK 232.10
Market Cap
SEK 63.27 Bil
Volume/Avg
364,370 / 735,355

Key Statistics

Price/Earnings (Normalized)
26.77
Price/Sales
1.99
Dividend Yield (Trailing)
1.90%
Dividend Yield (Forward)
1.90%
Total Yield
1.90%

Company Profile

Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (34%), and life sciences (14%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales (U.S. 33% of sales), Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
11,862
Website
https://www.getinge.com

Competitors

Valuation

View More
Metric
GETI B
MDT
TFX
Price/Earnings (Normalized)
 26.7714.9614.55
Price/Book Value
 1.982.082.08
Price/Sales
 1.993.343.13
Price/Cash Flow
 14.0414.7314.47
Price/Earnings
GETI B
MDT
TFX

Financial Strength

Metric
GETI B
MDT
TFX
Quick Ratio
 1.001.461.10
Current Ratio
 1.692.302.32
Interest Coverage
 9.138.865.95
Quick Ratio
GETI B
MDT
TFX

Profitability

Metric
GETI B
MDT
TFX
Return on Assets (Normalized)
 4.79%7.75%5.96%
Return on Equity (Normalized)
 8.20%13.75%10.10%
Return on Invested Capital (Normalized)
 7.34%9.87%7.98%
Return on Assets
GETI B
MDT
TFX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesShqxrbxJfnrqbb$184.3 Bil
SYK
Stryker CorpClxkynxlMyl$125.0 Bil
MDT
Medtronic PLCKybyfymPjvlx$107.4 Bil
BSX
Boston Scientific CorpFyzrbzhccVsvtlgg$106.2 Bil
EW
Edwards Lifesciences CorpWvqgzzkskTwvkd$50.8 Bil
DXCM
DexCom IncXtvdtmkjYpjv$50.1 Bil
ZBH
Zimmer Biomet Holdings IncYhjfjrxgdXbk$24.6 Bil
PHG
Koninklijke Philips NV ADRKbgfrqdMvzqfnx$24.5 Bil
ALGN
Align Technology IncLlvwzxzgGryywq$21.4 Bil
PODD
Insulet CorpHgzbmblyhjKwbmrtf$12.1 Bil

Sponsor Center